178 related articles for article (PubMed ID: 17393120)
1. Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line.
Guo D; Han L; Shu K; Chen J; Lei T
J Huazhong Univ Sci Technolog Med Sci; 2007 Feb; 27(1):91-4. PubMed ID: 17393120
[TBL] [Abstract][Full Text] [Related]
2. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors.
Guo D; Nilsson J; Haapasalo H; Raheem O; Bergenheim T; Hedman H; Henriksson R
Acta Neuropathol; 2006 Mar; 111(3):238-46. PubMed ID: 16532360
[TBL] [Abstract][Full Text] [Related]
3. LRIG and cancer prognosis.
Lindquist D; Kvarnbrink S; Henriksson R; Hedman H
Acta Oncol; 2014 Sep; 53(9):1135-42. PubMed ID: 25180912
[TBL] [Abstract][Full Text] [Related]
4. Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity.
Wu X; Hedman H; Bergqvist M; Bergström S; Henriksson R; Gullbo J; Lennartsson J; Hesselius P; Ekman S
Acta Oncol; 2012 Jan; 51(1):69-76. PubMed ID: 21417672
[TBL] [Abstract][Full Text] [Related]
5. LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease.
Karlsson T; Kvarnbrink S; Holmlund C; Botling J; Micke P; Henriksson R; Johansson M; Hedman H
Lung Cancer; 2018 Nov; 125():174-184. PubMed ID: 30429017
[TBL] [Abstract][Full Text] [Related]
6. Characterization and tissue-specific expression of human LRIG2.
Holmlund C; Nilsson J; Guo D; Starefeldt A; Golovleva I; Henriksson R; Hedman H
Gene; 2004 May; 332():35-43. PubMed ID: 15145052
[TBL] [Abstract][Full Text] [Related]
7. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
[TBL] [Abstract][Full Text] [Related]
9. Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.
Cheng SQ; Fan HY; Xu X; Gao WW; Lv SG; Ye MH; Wu MJ; Shen XL; Cheng ZJ; Zhu XG; Zhang Y
J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):558-563. PubMed ID: 27465333
[TBL] [Abstract][Full Text] [Related]
10. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
Qi XC; Xie DJ; Yan QF; Wang YR; Zhu YX; Qian C; Yang SX
Biochem Biophys Res Commun; 2013 Aug; 437(4):565-72. PubMed ID: 23850692
[TBL] [Abstract][Full Text] [Related]
11. Redistribution of LRIG proteins in psoriasis.
Karlsson T; Mark EB; Henriksson R; Hedman H
J Invest Dermatol; 2008 May; 128(5):1192-5. PubMed ID: 18037903
[TBL] [Abstract][Full Text] [Related]
12. In vivo analysis of Lrig genes reveals redundant and independent functions in the inner ear.
Del Rio T; Nishitani AM; Yu WM; Goodrich LV
PLoS Genet; 2013; 9(9):e1003824. PubMed ID: 24086156
[TBL] [Abstract][Full Text] [Related]
13. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2.
Xiao Q; Tan Y; Guo Y; Yang H; Mao F; Xie R; Wang B; Lei T; Guo D
PLoS One; 2014; 9(10):e111419. PubMed ID: 25353163
[TBL] [Abstract][Full Text] [Related]
14. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT--PCR and immunohistochemical analysis.
Thomasson M; Hedman H; Guo D; Ljungberg B; Henriksson R
Br J Cancer; 2003 Oct; 89(7):1285-9. PubMed ID: 14520461
[TBL] [Abstract][Full Text] [Related]
15. [Gene therapy study on bladder cancer with recombinant adenoviral vector carrying LRIG1 gene driven by Survivin promoter].
Yan ZJ; Cheng Y; Jiang JH; Hu JS; Shi XD
Zhonghua Wai Ke Za Zhi; 2012 Aug; 50(8):732-6. PubMed ID: 23157908
[TBL] [Abstract][Full Text] [Related]
16. LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers.
Malik U; Javed A
Curr Cancer Drug Targets; 2017; 17(1):3-16. PubMed ID: 27628597
[TBL] [Abstract][Full Text] [Related]
17. Expression of LRIG1 in pituitary tumor and its clinical significance.
Jie G; Guozheng X; Ying L; Yi Z; Bo D
Eur Rev Med Pharmacol Sci; 2016 May; 20(10):1969-73. PubMed ID: 27249594
[TBL] [Abstract][Full Text] [Related]
18. Loss of Lrig1 leads to expansion of Brunner glands followed by duodenal adenomas with gastric metaplasia.
Wang Y; Shi C; Lu Y; Poulin EJ; Franklin JL; Coffey RJ
Am J Pathol; 2015 Apr; 185(4):1123-34. PubMed ID: 25794708
[TBL] [Abstract][Full Text] [Related]
19. Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma.
Muller S; Lindquist D; Kanter L; Flores-Staino C; Henriksson R; Hedman H; Andersson S
Int J Oncol; 2013 Jan; 42(1):247-52. PubMed ID: 23165628
[TBL] [Abstract][Full Text] [Related]
20. The LRIG family: enigmatic regulators of growth factor receptor signaling.
Simion C; Cedano-Prieto ME; Sweeney C
Endocr Relat Cancer; 2014; 21(6):R431-43. PubMed ID: 25183430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
